Letian Huang

发表

The influence of tumor heterogeneity on sensitivity of EGFR-mutant lung adenocarcinoma cells to EGFR-TKIs

Jie-tao Ma, Cheng-Bo Han, Li Sun, 2019, Translational cancer research.

Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis

Jie-tao Ma, Cheng-Bo Han, Li Sun, 2020, Radiation Oncology.

Postoperative radiotherapy and tumor recurrence after complete resection of stage II/III thymic tumor: a meta-analysis of cohort studies

Jie-tao Ma, Cheng-Bo Han, Xin Sun, 2016, OncoTargets and therapy.

Impact of pulmonary interstitial lesions on efficacy and prognosis of EGFR-TKI-treated advanced non-small cell lung cancers

Xiang-yan Zhang, Jie-tao Ma, Cheng-Bo Han, 2020, Journal of thoracic disease.

Chest Wall Toxicity After Stereotactic Body Radiation Therapy: A Pooled Analysis of 57 Studies.

F. Kong, M. Milano, Jie-tao Ma, 2017, International journal of radiation oncology, biology, physics.

Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials

Jie-tao Ma, Cheng-Bo Han, Li Sun, 2020, BMC cancer.

Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs

Jing Sun, Jie-tao Ma, Cheng-Bo Han, 2018, Medicine.

Is pulmonary artery a dose-limiting organ at risk in non-small cell lung cancer patients treated with definitive radiotherapy?

Jie-tao Ma, Cheng-Bo Han, Yang Liu, 2017, Radiation Oncology.

Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis

X. Yi, Jie-tao Ma, Cheng-Bo Han, 2022, Frontiers in Oncology.

Retraction Note to: The Influence of mtDNA Deletion on Lung Cancer Cells Under the Conditions of Hypoxia and Irradiation

Jie-tao Ma, Cheng-Bo Han, Li Sun, 2014, Lung.

RETRACTED ARTICLE: The Influence of mtDNA Deletion on Lung Cancer Cells Under the Conditions of Hypoxia and Irradiation

Jie-tao Ma, Cheng-Bo Han, Li Sun, 2014, Lung.

Synergistic cytotoxic effects of recombinant human adenovirus p53 and radiation at various time points in A549 lung adenocarcinoma cells.

Jie-tao Ma, Cheng-Bo Han, Letian Huang, 2012, Oncology letters.

Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies

X. Yi, Cheng-Bo Han, Li Sun, 2022, Frontiers in Pharmacology.

Expression profiles of tRNA-derived fragments and their potential roles in lung adenocarcinoma

Y. Shimada, Mario Silva, K. Okuda, 2021, Annals of translational medicine.

Durable Clinical Response to Pyrotinib After Resistance to Prior Anti-HER2 Therapy for HER2-Positive Advanced Gastric Cancer: A Case Report

Cheng-Bo Han, Li Sun, Shuling Zhang, 2019, Front. Oncol..

Effects of Dynamin-related Protein 1 Regulated Mitochondrial Dynamic Changes on Invasion and Metastasis of Lung Cancer Cells

Cheng-Bo Han, Xiangyan Zhang, Li Sun, 2019, Journal of Cancer.

Short-term outcomes and safety of radiotherapy for immediate breast reconstruction with autologous flap transfer following breast-conserving surgery

Cheng-Bo Han, Li Sun, Shuling Zhang, 2020, BMC cancer.

Rational application of the first‐line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta‐analysis

Cheng-Bo Han, Yang Liu, Li Sun, 2019, Cancer medicine.

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

Cheng-Bo Han, Li Sun, Shuling Zhang, 2020, Frontiers in Oncology.

Recent Progress in Rare Oncogenic Drivers and Targeted Therapy For Non-Small Cell Lung Cancer

Cheng-Bo Han, Li Sun, Letian Huang, 2019, OncoTargets and therapy.

Impact of Drp1-Mediated Mitochondrial Dynamics on T Cell Immune Modulation

Cheng-Bo Han, Li Sun, Shuling Zhang, 2022, Frontiers in Immunology.

Expression of HGF, MET and mutated EGFR in EGFR mutated lung adenocarcinoma and their clinical significance

Cheng-Bo Han, Xin Sun, Li Sun, 2017 .

Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials

Cheng-Bo Han, Li Sun, Shuling Zhang, 2021, Frontiers in Oncology.

Prognostic and clinicopathologic significance of PLIN2 in cancers: A systematic review with meta-analysis

Letian Huang, Jia-He Wang, Ziyao Quan, 2023, The International journal of biological markers.

The Therapeutic Intervention of Sex Steroid Hormones for Sarcopenia

Jia-he Wang, Letian Huang, 2021, Frontiers in Medicine.

Dual antitumor immunomodulatory effects of PARP inhibitor on the tumor microenvironment: A counterbalance between anti-tumor and pro-tumor.

X. Yi, Cheng-Bo Han, Li Sun, 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Rational Application of First-Line EGFR-TKIs Combined with Antiangiogenic Inhibitors in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Cheng-Bo Han, Li Sun, Shuling Zhang, 2021, BioMed research international.

Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer.

Cheng-Bo Han, Shuling Zhang, Letian Huang, 2022, Lung cancer.

Is pulmonary artery a dose-limiting organ at risk in non-small cell lung cancer patients treated with definitive radiotherapy?

Cheng-Bo Han, Yang Liu, Xin Sun, 2017, Radiation oncology.

Prevalence of sarcopenia among patients with hepatocellular carcinoma: A systematic review and meta‑analysis

Letian Huang, Jiahe Wang, Jiye Liu, 2023, Oncology letters.

Postoperative radiotherapy and tumor recurrence after complete resection of stage II/III thymic tumor: a meta-analysis of cohort studies

Cheng-Bo Han, Xin Sun, Shuling Zhang, 2016, OncoTargets and therapy.

Untargeted lipidomic analysis and network pharmacology for parthenolide treated papillary thyroid carcinoma cells

Yi-Bing Wang, Letian Huang, Jia-He Wang, 2023, BMC Complementary Medicine and Therapies.

Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials

X. Yi, Cheng-Bo Han, Li Sun, 2023, BMC Cancer.